Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych CASC / OSCEPsychopharmacology — metabolic syndrome and psychotropic monitoring

Psych CASC / OSCE · Psychopharmacology — metabolic syndrome and psychotropic monitoring

Explaining antipsychotic weight gain and a monitoring plan (CASC)

CASC-style station: explain metabolic risk in plain language, validate anger, negotiate monitoring and change options (lifestyle, switch, metformin) without abandoning relapse prevention.

communication
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
Parents of a 17-year-old with first-episode psychosis are angry that olanzapine has 'made him fat and pre-diabetic' after 10 weeks (plus 8 kg, raised fasting glucose). They want all medication stopped today. The young person is improved and wants to stay well for school exams.

Station instructions (candidate)

You have 7 minutes with the parents (and young person if present). Validate concern about weight and glucose, explain that some antipsychotics — including olanzapine — carry higher metabolic risk especially in young people, outline what monitoring should look like, and negotiate a plan: lifestyle support, possible switch to a lower-metabolic agent, possible metformin, and why abrupt stop of all treatment risks relapse. Avoid jargon without explanation. Do not promise zero risk. Do not dismiss their anger.[1][2][6]

Marking domains

Empathy and agenda setting; accurate plain-language metabolic explanation; youth risk awareness; structured monitoring plan; collaborative options (switch/metformin/lifestyle); relapse-risk balance; shared decision and written follow-up; avoids both minimisation and “stop everything” panic.[1][2][3]

Model communication map

  1. Open: thank them for raising this; name shared goals — keep him well for school and protect long-term physical health.[1]
  2. Validate: weight and glucose changes are real, expected more with some medicines, and more concerning in adolescents; you should have been tracking this early.[2][6]
  3. Plain mechanism: some medicines increase hunger and change how the body handles sugar and fat — not a moral failure of the family.[6]
  4. Why medicine helped: reduced psychosis symptoms; sudden full stop risks return of illness that also harms life expectancy and safety.[1]
  5. Options now: (a) structured lifestyle support; (b) switch to a medicine with lower average weight effect if symptoms allow; (c) discuss metformin as an add-on studied for antipsychotic weight problems; (d) treat abnormal glucose with medical colleagues.[3][4][5]
  6. Monitoring promise: weight/waist/BP and labs on a clear timetable (early weeks then regular reviews) with named responsibility (clinic vs GP).[1]
  7. Safety-net: thirst, lots of urine, vomiting, confusion → urgent care for possible dangerous high sugar.[1]
  8. Close: summarise plan, written leaflet, follow-up date, invite questions.[1]

Common fails

  • “All antipsychotics are the same for weight.”[6]
  • Agreeing to stop all medicine today with no relapse plan.[1]
  • Blaming parents’ cooking as the sole cause.[2]
  • Offering metformin without mentioning monitoring, side effects, or that lifestyle still matters.[3][4]
  • Using only acronyms (MetS, SGA, HbA1c) without checking understanding.[1]

References

  1. [1]American Diabetes Association, American Psychiatric Association, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care, 2004.PMID 14747245
  2. [2]Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents JAMA, 2009.PMID 19861668
  3. [3]Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial JAMA, 2008.PMID 18182600
  4. [4]Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder Am J Psychiatry, 2013.PMID 23846733
  5. [5]Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine J Clin Psychiatry, 2008.PMID 18605811
  6. [6]Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry, 1999.PMID 10553730